FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number: 30457.0013USWO

Application Number: 10/550,165

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: Paul Savage et al.

Filing Date: July 21, 2006 Group Art Unit: 1623

EXAMINER	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS		DATE
INITIAL						IF APPRO	OPRIATE
	2005/0222048	10/06/2005	Tsuji et al.				
	2006/0211856	09/21/2006	Tsuji et al.				
	2005/0192248	09/01/2005	Tsuji et al.				
	2004/0166554	08/26/2004	Chamoles				
	2009/0047299	02/19/2009	Savage				
	2006/0019246	01/26/2006	Tsuji et al.				
	5,242,800	09/07/1993	Jimenez et al.				
	5,785,975	07/28/1998	Parikh			-	
	5,958,426	09/28/1999	Moreau et al.				
	6,417,167	07/09/2002	Maruyama et al.				
	6,610,835	08/26/2003	Liotta et al.				
	6,635,622	10/21/2003	Tomiyama et al.				
		FOR	EIGN PATENT DOCUM	IENTS			
	DOCUMENT NO.	ENT NO. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
				1		YES	NO
	EP 0988860	03/29/2000	EP				
	EP 1016409	07/05/2000	EP				
	WO 99/33475	07/08/1999	PCT				
······································	WO 03/009812	02/06/2003	PCT				
	WO 03/105769	12/24/2003	PCT	·			
	WO 05/102049	11/03/2005	PCT				
	WO 06/029010	03/16/2006	PCT				
	WO 07/050668	05/03/2007	PCT				
	OTHER	DOCUMENTS	S (Including Author, Title,	Date, Pertinent I	Pages, Etc.)		•
			KT cells inhibit the onset of c beta cells," Immunity (20			ment of patho	ogenic T

EXAMINER	
-----------------	--

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 30457.0013USWO	Application Number: 10/550,165
IN AN APPLICATION	Applicant: Paul Savage et al.	
(Use several sheets if necessary)	Filing Date: July 21, 2006	Group Art Unit: 1623

1:177-186
BENDELAC, A. et al., "The biology of NKT cells," Ann. Rev. Immunol. (2007) 25:297-336
BENDELAC, A., "Nondeletional pathways for the development of autoreactive thymocytes," Nat. Immunol. (2004) 5:557-558
BROSSAY, L. et al., "Cutting edge: structural requirements for galactosylceramide recognition by CD1-restricted NK T cells," J. Immunol. (1998) 161(10):5124-5128
DAOUDI, J-M. et al., "New bicyclam-galcer analogue conjugates: synthesis and in vitro anti-HIV activity," Biorg. Med. Chem. Lett. (2004) 14:495-498
DE LIBERO, G. et al., "Self glycosphingolipids: new antigens recognized by autoreactive T lymphocytes," News Physiol. Sci. (2003) 18:71-76
European Office Action for Application No. 05810863.0 dated April 2, 2008 (4 pages)
FISCHER, K. et al., "Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells," Proc. Natl. Acad. Sci. USA (2004) 101:10685-10690
GOODMAN & GILMAN's The Pharmacological Basis of Therapeutics, Tenth Edition, Hardman and Limbird, editors, The McGraw-Hill Companies, Inc., New York, (2001) 54-56
GUMPERZ, J.E. et al., "Murine CD1d-restricted T cell recognition of cellular lipids," Immunity (2000) 12:211-221
GUPTA, R.K. et al., "Adjuvants - a balance between toxicity and adjuvanticity," Vaccine (1993) 11(3):293-306
HONEY, K. et al., "Thymocyte expression of cathepsin L is essential for NKT cell development," Nat. Immunol. (2002) 3:1069-1074
International Search Report and Written Opinion for Application No. PCT/US2005/031407 (13 pages)
ISLAM, I. et al., "Synthesis and antiviral activity of (2-((4-(3-((1-methylethyl)amino)-2-pyridyl)-1-piperazinyl)carbony)-1H-indo 1-5-yl) (BHAP) acylspingosine HIV reverse transcriptase inhibitors," Biorg. Chem. (1995) 23(4):499-511
KITAMURA, H. et al., "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells," J. Exp. Med. (1999) 189:1121-1127
PARK, SH. et al., "Tissue-specific recognition of mouse CD1 molecules," J. Immunol. (1998) 160:3128-3134
PRIGOZY, T.I. et al., "Glycolipid antigen processing for presentation by CD1d molecules," Science (2001) 291:664-667
SMYTH, M.J. et al., "NKT cells - conductors of tumor immunity?" Curr. Opin. Immunol. (2002) 14(2):165-171
SMYTH, M.J. et al., "NKT cells and tumor immunity - a double-edged sword," Nature Immunology (2001) 1:459-460
STANIC A.K. et al., "Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by Beta-D-glucosylceramide synthase deficiency," Proc. Natl. Acad. Sci. USA (2003) 100:1849-1854

EXAMINER	DATE CONSIDERED
	I was the same of

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Date Mailed: April 27, 2009 Sheet 3 of 3

FORM 1449*	INFORMATION DISCLOSURE STATEMENT	Docket Number: 30457.0013USWO	Application Number: 10/550,165	
	IN AN APPLICATION	Applicant: Paul Savage et al.		
	(Use several sheets if necessary)	Filing Date: July 21, 2006	Group Art Unit: 1623	

tates Office Action for Application No. 11/771,128 dated October 29, 2008 (14 pages)
CR VLIET, H.J.J. et al., "Effects of α-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 stype and cytokine profile of human $V\alpha 24 + V\beta 11 + T$ cells," Immunology (1999) 98:557-563
MMELEN, S.L.H. et al., "Activation of natural killer (NK) T cells during murine cytomegalovirus enhances the antiviral response mediated by NK cells," J. Virology (2003) 77(3):1877-1884
F. et al., "Saposin C is required for lipid presentation by human CD1b," Nat. Immunol. (2004) 5:169-
7. et al., "Cross-presentation of disialoganglioside GD3 to natural killer T cells," J. Exp. Med. (2003) 181
et al., "Thio-isoglobotrihexosylceramide, an Agonist for activating invariant natural killer T cells," Org 06) 8(24):5493-5496
C, D.M. et al., "Structural basis for CD1d presentation of a sulfatide derived from myelin and its ons for autoimmunity," J. Exp. Med. (2005) 202(11):1517-1526
D. et al., "Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins," Science (2004) 527
D., "The immunological function of iGb3," Curr. Prot. Pept. Sci. (2006) 7:325-333

23552
PATENT TRADEMARK OFFICE

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.